Erratum to: Rationale and design of oBservational clinical Research In chronic kidney disease patients with renal anemia: renal proGnosis in patients with Hyporesponsive anemia To Erythropoiesis-stimulating agents, darbepoetiN alfa (BRIGHTEN Trial) (Clinical and Experimental Nephrology, (2018), 22, 1, (78-84), 10.1007/s10157-017-1427-4)

Hideki Kato, Masaomi Nangaku, Hideki Hirakata, Takashi Wada, Terumasa Hayashi, Hiroshi Sato, Yasushi Yamazaki, Takao Masaki, Tatsuo Kagimura, Hiroyasu Yamamoto, Hiroki Hase, Masahiro Kamouchi, Enyu Imai, Kyoichi Mizuno, Manabu Iwasaki, Tadao Akizawa, Yoshiharu Tsubakihara, Shoichi Maruyama, Ichiei Narita

Research output: Contribution to journalComment/debate

Abstract

The article Rationale and design of oBservational clinical Research In chronic kidney disease patients with renal anemia: renal prognosis in patients with Hyporesponsive anemia To Erythropoiesis-stimulating agents, darbepoetiN alfa (BRIGHTEN Trial), written by Hideki Kato, Masaomi Nangaku, Hideki Hirakata, Takashi Wada, Terumasa Hayashi, Hiroshi Sato, Yasushi Yamazaki, Takao Masaki, Tatsuo Kagimura, Hiroyasu Yamamoto, Hiroki Hase, Masahiro Kamouchi, Enyu Imai, Kyoichi Mizuno, Manabu Iwasaki, Tadao Akizawa, Yoshiharu Tsubakihara, Shoichi Maruyama, and Ichiei Narita was originally published electronically on the publisher’s internet portal (currently SpringerLink) on June 28, 2017 without open access. With the author(s)’ decision to opt for Open Choice the copyright of the article changed on August 15, 2017 to

Original languageEnglish
Pages (from-to)85-86
Number of pages2
JournalClinical and experimental nephrology
Volume22
Issue number1
DOIs
Publication statusPublished - 2018 Feb 1

ASJC Scopus subject areas

  • Physiology
  • Nephrology
  • Physiology (medical)

Fingerprint Dive into the research topics of 'Erratum to: Rationale and design of oBservational clinical Research In chronic kidney disease patients with renal anemia: renal proGnosis in patients with Hyporesponsive anemia To Erythropoiesis-stimulating agents, darbepoetiN alfa (BRIGHTEN Trial) (Clinical and Experimental Nephrology, (2018), 22, 1, (78-84), 10.1007/s10157-017-1427-4)'. Together they form a unique fingerprint.

  • Cite this